The approval is particularly noteworthy due to the fact that, while antibody drug conjugates (ADCs), such as trastuzumab deruxtecan (T-DXd) have shown efficacy in HER2-mutant NSCLC, their clinical use has been constrained by concerns of toxicity, including interstitial lung disease (ILD), and the need for intravenous (i.v.)administration (vs. the oral administration routes of KIs) (Li et al., 2022[72]). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.